UCSF Medical Center
UCSF Medical Center
San Francisco, California, United States26 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation: | Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Surgical Wound Infection, Wound Infection | Not yet recruiting | Phase 3 | 2026-10-08 | NCT07458230 | |
| CAR-T Long Term Follow Up (LTFU) Study | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Recruiting | Phase 3 | 2026-10-02 | NCT02445222 | |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Chemically-Induced Disorders, Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, alcohol-induced disorders, alcohol-related disorders, alcoholic liver cirrhosis, alcoholic liver disease, cirrhosis of liver, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, substance-related disorder | Recruiting | Phase 2 | 2026-09-28 | NCT05832229 | |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Not yet recruiting | Phase 4 | 2026-09-24 | NCT07502339 | |
| Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT01872260 | |
| Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT) | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Status Epilepticus, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-09-17 | NCT06907173 | |
| The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms | Aneurysm, Bites and Stings, Chemically-Induced Disorders, Fusiform Aneurysm, Saccular Aneurysm, brain aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hemorrhagic stroke, injury, intracranial arterial disease, nervous system disorder, poisoning, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-09-09 | NCT07143019 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-09-09 | NCT05633654 | |
| Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Clear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-08-27 | NCT04696731 | |
| Biomarkers of Cervical Spondylotic Myelopathy | Cervical Spondylotic Myelopathy | Not yet recruiting | Not stated | 2026-08-20 | NCT07772297 | |
| Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials | Stroke, Acute, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not stated | 2026-08-20 | NCT05338697 | |
| Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 2 | 2026-08-19 | NCT03876769 | |
| Delayed Toxicities Post-CAR-T | Blood Protein Disorders, Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, nervous system disorder, plasma cell neoplasm, poisoning, toxic encephalopathy, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-08-10 | NCT07665307 | |
| PROACTIVE-HF IDE Trial Heart Failure NYHA Class III | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Not applicable | 2026-07-24 | NCT04089059 | |
| Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Phase 1 | 2026-06-30 | NCT06201416 | |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-06-29 | NCT05934487 | |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cancer, carcinoma, cervix disorder, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, squamous cell neoplasm, stomach disorder, triple-negative breast carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Enrolling by invitation | Phase 1 | 2026-06-11 | NCT07218003 | |
| Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms | Aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder, vasculitis | Recruiting | Phase 1 / Phase 2 | 2026-06-11 | NCT02638701 | |
| A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, arthritic joint disease, arthropathy, autoimmune disease, bacterial infectious disease, connective tissue disorder, hidradenitis, hidradenitis suppurativa, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Not stated | 2026-04-16 | NCT07123038 | |
| Citadel Embolization Device Study | Unruptured Wide-neck Aneurysms | Active, not recruiting | Not applicable | 2026-03-30 | NCT04057352 | |
| Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-03-12 | NCT04417621 | |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | aortic valve disorder, aortic valve stenosis, cardiomyopathy, cardiovascular disorder, heart disorder, heart valve disorder, hypertrophic cardiomyopathy, subvalvular aortic stenosis | Enrolling by invitation | Phase 2 / Phase 3 | 2026-01-22 | NCT04848506 | |
| Liver Cirrhosis Network Cohort Study | Chemically-Induced Disorders, Cirrhosis, Cryptogenic, Digestive System Diseases, Fibrosis, Hepatitis, Chronic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, alcohol-induced disorders, alcohol-related disorders, alcoholic liver cirrhosis, alcoholic liver disease, autoimmune disease, autoimmune hepatitis, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, fatty liver disease, hepatitis, immune system disorder, intrahepatic cholestasis, liver disorder, metabolic dysfunction-associated steatotic liver disease, primary biliary cholangitis, substance-related disorder | Active, not recruiting | Not stated | 2026-01-13 | NCT05740358 | |
| A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-12-19 | NCT05249101 | |
| Pulmonary Hypertension Association Registry | cardiovascular disorder, chronic thromboembolic pulmonary hypertension, hypertensive disorder, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, vascular disorder | Recruiting | Not stated | 2025-11-14 | NCT04071327 |